GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (HKSE:02196) » Definitions » Cash Flow for Dividends

Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Cash Flow for Dividends : HK$-2,669 Mil (TTM As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co Cash Flow for Dividends?

Shanghai Fosun Pharmaceutical (Group) Co's cash flow for dividends for the three months ended in Dec. 2023 was HK$-396 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2,669 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Shanghai Fosun Pharmaceutical (Group) Co's quarterly payment of dividends increased from Jun. 2023 (HK$-328 Mil) to Sep. 2023 (HK$-1,575 Mil) but then declined from Sep. 2023 (HK$-1,575 Mil) to Dec. 2023 (HK$-396 Mil).

Shanghai Fosun Pharmaceutical (Group) Co's annual payment of dividends increased from Dec. 2021 (HK$-2,344 Mil) to Dec. 2022 (HK$-2,651 Mil) and increased from Dec. 2022 (HK$-2,651 Mil) to Dec. 2023 (HK$-2,685 Mil).


Shanghai Fosun Pharmaceutical (Group) Co Cash Flow for Dividends Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Cash Flow for Dividends Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,074.66 -2,174.84 -2,343.58 -2,651.49 -2,685.41

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -291.57 -370.15 -328.33 -1,574.84 -395.85

Shanghai Fosun Pharmaceutical (Group) Co Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-2,669 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Fosun Pharmaceutical (Group) Co Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Business Description

Traded in Other Exchanges
Address
No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Headlines

No Headlines